Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Gazyva Succeeds In NOBILITY Lupus Nephritis Study But What Next?

Tue, 06/11/2019 - 7:54am

Genentech refrained from committing to further development of its CD20 inhibitor in the indication despite meeting endpoints in Phase II...

      Related Stories 

Xenikos Set To Start Phase III For Acute GVHD Drug

Tue, 06/11/2019 - 7:12am

The Dutch biotech's CEO tells Scrip that one-week treatment with T-Guard could change the paradigm for tackling steroid-refractory graft-versus-host disease.

      Related Stories 

Aurobindo Upbeat On Outlook As It Moves To Close Sandoz Deal

Mon, 06/10/2019 - 10:13pm

India's Aurobindo says it is betting its $1bn purchase of Sandoz' US dermatology assets will help “really fuel growth” and...

      Related Stories 

Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals

Mon, 06/10/2019 - 2:27pm

CF-focused Vertex will buy Exonics and expand a collaboration with CRISPR Therapeutics, with plans to develop therapies for DMD and...

      Related Stories 

Questions Persist On Lilly’s Tirzepatide And Tolerability

Mon, 06/10/2019 - 1:36pm

Concerns about gastrointestinal tolerability continue to weigh on Lilly’s tirzepatide, despite improvements seen in a Phase II dose-escalation study. Lilly...

      Related Stories 

Lilly's Trulicity Shows Unique Cardiovascular Outcomes Benefit, Albeit A Modest One

Mon, 06/10/2019 - 1:31pm

At the ADA annual meeting, Lilly reported positive results from REWIND, a cardiovascular outcomes trial studying the GLP-1 agonist Trulicity...

      Related Stories 

CHART/TABLE: Pipeline Watch: ASCO Meeting Dominates Trial Updates

Mon, 06/10/2019 - 9:55am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

AZ's Farxiga Fillip As Drug Reduces Renal Disease Risk In Type 2 Diabetics

Mon, 06/10/2019 - 8:36am

AstraZeneca has presented more data on Farxiga at the American Diabetes Association meeting which should help the SGLT2 inhibitor in...

      Related Stories 

GC Pharma Hones R&D Focus, Tweaks US Immunoglobulin Strategy

Sun, 06/09/2019 - 7:20pm

Leading South Korean pharma firm GC Pharma realigns R&D priorities and resources and changes US strategy amid delayed approval of...

      Related Stories 

Amyloidosis Drug Competitors Can Coexist While Growing The Market, Alnylam CEO Says

Fri, 06/07/2019 - 3:51pm

The recent US FDA approval of three drugs – Alnylam’s Onpattro, Ionis’ Tegsedi and Pfizer’s tafamidis – in transthyretin-mediated amyloidosis...

      Related Stories 

Venture Funding Deals: Takeda's Phathom Raises $140m In Crossover Round For GERD Program

Fri, 06/07/2019 - 1:42pm

AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing...

      Related Stories 

The Challenges Facing Paul Hudson At the Helm of Sanofi

Fri, 06/07/2019 - 8:20am

Novartis’s erstwhile head of pharma will be tasked with making the French drug maker more agile on the commercial and...

      Related Stories 

Protalix and Chiesi Plan Q1 2020 Filing For Accelerated FDA Approval

Fri, 06/07/2019 - 6:57am

The companies plan to use surrogate endpoint data to win approval to challenge Sanofi and Shire for the Fabry disease...

      Related Stories 

Pages